A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma.

2.50
Hdl Handle:
http://hdl.handle.net/10541/56022
Title:
A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma.
Authors:
Jones, Robert J; Hawkins, Robert E; Eatock, Martin M; Ferry, David R; Eskens, Ferry A L M; Wilke, HansJochen; Evans, T R Jeffry
Abstract:
PURPOSE: Combination chemotherapy regimens can improve survival in patients with advanced gastric and oesophageal adenocarcinoma. Docosahexaenoic acid (DHA)-paclitaxel is a novel conjugate formed by the covalent linkage of the fatty acid DHA to paclitaxel and may result in increased tumour exposure to paclitaxel without increased toxicity. PATIENTS AND METHODS: In this single arm, phase II study of DHA-paclitaxel, eligible patients with previously untreated, inoperable locally advanced or metastatic adenocarcinoma of the oesophagus, oesophago-gastric junction or stomach were treated with DHA-paclitaxel (1,100 mg/m(2)) administered by 2-h intravenous infusion every 21 days. RESULTS: Fifty-four patients were recruited of whom 53 were evaluable for toxicity, and 48 for response. There were five confirmed partial responses (9.4%) by the RECIST criteria. The median duration of response was 87 days (range 49-97 days), the median time to progression was 84 days (95% CI 78-124 days), and median overall survival was 262 days (95% CI 205-357 days). Grade >or=3 neutropaenia occurred in 93% of patients, and febrile neutropaenia in 17% of patients. CONCLUSIONS: DHA-paclitaxel has modest activity in patients with oesophago-gastric cancer and with haematological toxicity that is comparable to paclitaxel and docetaxel.
Affiliation:
Centre for Oncology and Applied Pharmacology, Beatson Oncology Centre, Western Infirmary, University of Glasgow, UK.
Citation:
A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma. 2008, 61 (3):435-41 Cancer Chemother. Pharmacol.
Journal:
Cancer Chemotherapy and Pharmacology
Issue Date:
Mar-2008
URI:
http://hdl.handle.net/10541/56022
DOI:
10.1007/s00280-007-0486-8
PubMed ID:
17440725
Type:
Article
Language:
en
ISSN:
0344-5704
Appears in Collections:
All Paterson Institute for Cancer Research; Medical Oncology

Full metadata record

DC FieldValue Language
dc.contributor.authorJones, Robert J-
dc.contributor.authorHawkins, Robert E-
dc.contributor.authorEatock, Martin M-
dc.contributor.authorFerry, David R-
dc.contributor.authorEskens, Ferry A L M-
dc.contributor.authorWilke, HansJochen-
dc.contributor.authorEvans, T R Jeffry-
dc.date.accessioned2009-03-17T17:10:36Z-
dc.date.available2009-03-17T17:10:36Z-
dc.date.issued2008-03-
dc.identifier.citationA phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma. 2008, 61 (3):435-41 Cancer Chemother. Pharmacol.en
dc.identifier.issn0344-5704-
dc.identifier.pmid17440725-
dc.identifier.doi10.1007/s00280-007-0486-8-
dc.identifier.urihttp://hdl.handle.net/10541/56022-
dc.description.abstractPURPOSE: Combination chemotherapy regimens can improve survival in patients with advanced gastric and oesophageal adenocarcinoma. Docosahexaenoic acid (DHA)-paclitaxel is a novel conjugate formed by the covalent linkage of the fatty acid DHA to paclitaxel and may result in increased tumour exposure to paclitaxel without increased toxicity. PATIENTS AND METHODS: In this single arm, phase II study of DHA-paclitaxel, eligible patients with previously untreated, inoperable locally advanced or metastatic adenocarcinoma of the oesophagus, oesophago-gastric junction or stomach were treated with DHA-paclitaxel (1,100 mg/m(2)) administered by 2-h intravenous infusion every 21 days. RESULTS: Fifty-four patients were recruited of whom 53 were evaluable for toxicity, and 48 for response. There were five confirmed partial responses (9.4%) by the RECIST criteria. The median duration of response was 87 days (range 49-97 days), the median time to progression was 84 days (95% CI 78-124 days), and median overall survival was 262 days (95% CI 205-357 days). Grade >or=3 neutropaenia occurred in 93% of patients, and febrile neutropaenia in 17% of patients. CONCLUSIONS: DHA-paclitaxel has modest activity in patients with oesophago-gastric cancer and with haematological toxicity that is comparable to paclitaxel and docetaxel.en
dc.language.isoenen
dc.subjectDHA-Paclitaxelen
dc.subjectOesopheal Canceren
dc.subjectStomach Canceren
dc.subjectCancer Metastasis-
dc.subject.meshAdenocarcinoma-
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshAntineoplastic Agents, Phytogenic-
dc.subject.meshDisease Progression-
dc.subject.meshDose-Response Relationship, Drug-
dc.subject.meshEsophageal Neoplasms-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshInfusions, Intravenous-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasm Metastasis-
dc.subject.meshPaclitaxel-
dc.subject.meshStomach Neoplasms-
dc.subject.meshSurvival Analysis-
dc.subject.meshTomography, X-Ray Computed-
dc.titleA phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma.en
dc.typeArticleen
dc.contributor.departmentCentre for Oncology and Applied Pharmacology, Beatson Oncology Centre, Western Infirmary, University of Glasgow, UK.en
dc.identifier.journalCancer Chemotherapy and Pharmacologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.